How Much Do GLP-1 Drugs Cost, and Which Is Cheapest? (2026)

Direct Answer: GLP-1 Drug Costs in 2026

It depends on your insurance and the drug's FDA-approved indication. Without insurance, GLP-1 list prices in 2026 range from roughly $600/month for generic liraglutide to $1,349/month for Wegovy. Medicare Part D enrollees with a type 2 diabetes diagnosis can access Mounjaro (tirzepatide) through the Trump administration Most Favored Nation deal at $245/month with a $50 copay cap via TrumpRx. Commercial plans typically cover diabetes-indicated GLP-1s at a $30 to $70 copay; obesity-indicated versions may have no coverage at all.

What Medicare Part D Covers for GLP-1 Drugs (2026)

Medicare Part D covers GLP-1 drugs when they carry an FDA-approved indication for a condition Medicare recognizes. For 2026, three standard coverage pathways exist. First, diabetes-indicated GLP-1s (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity) are covered under Part D because type 2 diabetes is a recognized condition. Second, Wegovy gained Medicare Part D coverage in 2024 based on the FDA approval of its cardiovascular risk reduction label (the SELECT trial showed a 20% reduction in major cardiovascular events). Part D plans must cover Wegovy when prescribed to patients with established cardiovascular disease and a body mass index of 27 or higher. Third, Zepbound (tirzepatide for obstructive sleep apnea) became covered under Part D in 2025 because OSA is a recognized comorbidity, not a lifestyle condition.

Mounjaro (tirzepatide) pricing for Medicare Part D enrollees in 2026 comes through the Trump administration Most Favored Nation deal with Eli Lilly, not through the IRA Drug Price Negotiation Program. Tirzepatide is not among the 10 drugs whose IRA-negotiated Maximum Fair Prices took effect January 1, 2026 (those 10 are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp). Instead, the Trump administration announced a bilateral MFN arrangement with Eli Lilly setting Mounjaro's Medicare price at $245/month, with a $50 copay cap delivered through the TrumpRx platform. This deal was announced in 2025 and began rolling out in 2026. Medicare Part D enrollees should confirm whether their specific plan participates in TrumpRx delivery for the $50 copay cap, as implementation varies by plan. Additionally, the 2026 Medicare Part D out-of-pocket cap of $2,100 (set by the Inflation Reduction Act signed August 16, 2022) limits total annual Part D spending, which benefits patients on high-cost drugs including GLP-1s.

Medicare Part D does NOT cover GLP-1s prescribed solely for weight loss without a qualifying comorbidity. Saxenda (liraglutide 3mg) and Wegovy when prescribed only for obesity without cardiovascular disease remain excluded from Part D coverage. The 2003 Medicare Modernization Act prohibited Part D coverage of drugs used for obesity treatment, and while the cardiovascular and OSA labels create exceptions, the exclusion still applies to straightforward weight-loss prescriptions. Starting July 2026, however, the CMS GLP-1 Demonstration Program creates a new pathway: qualifying Medicare beneficiaries can access Wegovy and Zepbound for obesity alone (without a cardiovascular or OSA comorbidity) at approximately $50/month copay through participating plans in the demonstration.

ACA Marketplace and Commercial Insurance Coverage

ACA-compliant plans are required to cover all 10 Essential Health Benefits, but weight-loss drugs are not an Essential Health Benefit. ACA marketplace plans are not required to cover obesity-indicated GLP-1s (Wegovy, Saxenda, Zepbound when prescribed for weight loss). Diabetes-indicated GLP-1s fall within the prescription drug Essential Health Benefit for plans that include diabetes medications in their formularies, though tiered placement and prior authorization requirements vary by plan.

Large employer-sponsored plans (self-insured plans governed by ERISA) have wider discretion. Many large employers added Wegovy or Zepbound coverage in 2024 to 2025 but then removed it due to cost. A 2025 KFF survey found that roughly 28% of large employers covered at least one obesity-indicated GLP-1. Coverage decisions often include prior authorization requirements, BMI thresholds (usually BMI 30 or higher, or 27 or higher with a comorbidity), and participation in a concurrent lifestyle program. ACA subsidy cliffs returned for 2026 after enhanced premium tax credits from the American Rescue Plan Act expired January 1, 2026, which affects how many people can afford ACA marketplace coverage to begin with.

Medicaid Coverage of GLP-1 Drugs by State

Medicaid coverage of GLP-1 drugs varies significantly by state. See does Medicaid cover GLP-1 drugs by state. The federal Medicaid program does not mandate coverage of obesity-indicated drugs, so coverage of Wegovy, Saxenda, and Zepbound (for obesity) is at each state's discretion. As of 2026, fewer than 10 states have added obesity-indicated GLP-1 coverage to their Medicaid formularies; the cost impact on state budgets is the primary barrier.

Diabetes-indicated GLP-1s (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity) are covered under most state Medicaid programs because diabetes management is a covered benefit. However, Medicaid programs typically use formulary management and prior authorization to control costs. A state Medicaid plan may cover liraglutide (Victoza) or dulaglutide (Trulicity) as preferred agents and require step therapy (trying an older drug first) before covering semaglutide or tirzepatide. Step therapy requirements are common for Ozempic and Mounjaro in Medicaid formularies. Check your state Medicaid agency's drug formulary for current tier placement.

Cost Without Insurance: What You Actually Pay in 2026

Without insurance, GLP-1 drugs are among the most expensive prescription drugs in the United States. See detailed pricing for Mounjaro and Zepbound. The 2026 Wholesale Acquisition Cost (WAC, the list price before any rebates or discounts) for the major GLP-1s ranges as follows: Saxenda approximately $1,400/month, Wegovy approximately $1,349/month, Mounjaro approximately $1,069/month, Zepbound approximately $1,059/month, Rybelsus approximately $900/month, Ozempic approximately $935/month, Trulicity approximately $850/month, Victoza brand approximately $650/month. Generic liraglutide (equivalent to Victoza) is available and priced lower, though generic GLP-1 pricing varies by pharmacy and is still substantially above older diabetes drug generics.

GoodRx and similar discount programs can reduce out-of-pocket costs by 20 to 40% at participating pharmacies. Novo Nordisk and Eli Lilly each run patient assistance programs: the Novo Nordisk Patient Assistance Program covers Ozempic, Wegovy, and Rybelsus for uninsured or underinsured patients at certain income levels (generally below 400% of the Federal Poverty Level); the Eli Lilly LillyAnswers program offers similar income-based assistance for Mounjaro and Zepbound. Eligibility and benefit levels change periodically, so check the manufacturer's website directly.

Why Diabetes vs Obesity Indication Changes Everything

The single biggest factor determining GLP-1 insurance coverage is whether the drug is prescribed for type 2 diabetes or for obesity. Semaglutide and tirzepatide are the same molecules in both cases, but the FDA-approved indications are different, and insurance coverage follows the indication. Ozempic (semaglutide) is approved for type 2 diabetes; Wegovy (semaglutide at a higher dose) is approved for chronic weight management. Medicare covers Ozempic under Part D for diabetes. Medicare covers Wegovy under Part D for cardiovascular risk reduction (not for obesity alone, outside the July 2026 CMS demonstration). ACA marketplace plans routinely cover Ozempic for diabetes; most do not cover Wegovy unless the cardiovascular indication is present.

Prescribing a drug off-label (using Ozempic for weight loss when the patient does not have diabetes) does not change coverage decisions. Insurers and Medicare cover drugs based on the indication, not off-label use. Ozempic is approved only for type 2 diabetes, not for obesity; using it off-label for weight loss is generally denied by insurers. A patient without a diabetes diagnosis who gets Ozempic prescribed for weight loss will generally not receive coverage under plans that require a diabetes diagnosis. The correct on-label path for obesity coverage is Wegovy with a cardiovascular risk diagnosis, Zepbound with an OSA diagnosis, or qualifying for a commercial plan that explicitly covers obesity-indicated GLP-1s.

Lower-Cost Options and Alternatives for GLP-1 Drugs

Several concrete pathways exist to lower GLP-1 costs in 2026. First, Medicare Part D enrollees with a type 2 diabetes diagnosis can access Mounjaro through the Trump administration Most Favored Nation deal at $245/month with a $50 copay cap via the TrumpRx platform, making it a significantly more affordable option than the $1,069/month list price. Confirm with your Part D plan whether TrumpRx delivery is available for your enrollment. Second, starting July 2026, the CMS GLP-1 Demonstration Program covers Wegovy and Zepbound for obesity alone (no CV or OSA comorbidity required) at approximately $50/month copay for eligible Medicare beneficiaries in participating plans. Third, the 2026 Medicare Part D out-of-pocket cap of $2,100 protects all Part D enrollees from catastrophic spending on any covered prescription drug, including GLP-1s.

Fourth, for patients who qualify for the GLP-1 Bridge Program, Wegovy is available at $50/month for specific comorbidity profiles: heart failure with preserved ejection fraction, uncontrolled hypertension, chronic kidney disease stage 3a or higher at BMI 30 or higher, or pre-diabetes, prior heart attack, stroke, or peripheral artery disease at BMI 27 or higher. Simple obesity alone does not qualify for the GLP-1 Bridge rate. Fifth, request your doctor consider an older diabetes GLP-1 first: generic liraglutide (available) and dulaglutide (Trulicity, generic pending) are more likely to be on preferred Medicaid and insurance formulary tiers at lower copays. Sixth, manufacturer patient assistance programs from Novo Nordisk (NovoCare) and Eli Lilly (LillyAnswers) provide free or deeply discounted medication for uninsured patients below approximately 400% of the Federal Poverty Level.

Compounded semaglutide has been available from compounding pharmacies during recent FDA shortage periods, sometimes at $100 to $300/month. As of 2026, FDA shortage status for semaglutide products shifts periodically. When a brand-name drug is not in shortage, compounded versions lose legal protection and FDA has taken enforcement action against some compounders. Compounded GLP-1s carry additional risks: variable dosing accuracy, no FDA review of the specific compound, and no coverage from any insurer. Factor these risks into any cost comparison.

How to Get Coverage Approved: Prior Authorization Steps

Most insurers and Medicare Part D plans require prior authorization (PA) for GLP-1 drugs. The approval criteria differ by drug and insurer, but a standard prior authorization for a diabetes-indicated GLP-1 in 2026 requires a type 2 diabetes diagnosis, documentation that first-line agents (metformin, an SGLT2 inhibitor, or a DPP-4 inhibitor) were tried or are contraindicated, an A1C level typically above 7.5% or 8%, and prescriber attestation that the GLP-1 is medically necessary. For obesity-indicated GLP-1s, PA criteria typically require a BMI of 30 or higher (or 27 or higher with a comorbidity), documentation of a supervised diet and exercise program, and no contraindications.

If a prior authorization is denied, you have the right to appeal. For Medicare Part D, you can request a Coverage Determination, then a Redetermination, then a Reconsideration by an Independent Review Entity, then an ALJ hearing, and finally a federal court review. The fastest path when clinically appropriate is for your prescriber to file an expedited appeal citing medical necessity. For commercial insurance, the No Surprises Act and state external review laws give you access to independent review if the internal appeal fails. Document everything: specific diagnosis codes, supporting lab values (A1C, BMI, lipid panel), and any comorbidities that qualify the drug for coverage.

Which GLP-1 drug is the cheapest in 2026?

For Medicare Part D enrollees with a type 2 diabetes diagnosis, Mounjaro (tirzepatide) is accessible through the Trump administration Most Favored Nation deal with Eli Lilly at $245/month with a $50 copay cap via TrumpRx, making it a low-cost option for Medicare patients. Starting July 2026, the CMS GLP-1 Demonstration also offers Wegovy and Zepbound for obesity at approximately $50/month copay. Without insurance, generic liraglutide (Victoza equivalent) is typically the lowest-cost GLP-1 option, though still several hundred dollars per month. Saxenda ($1,400/month) and Wegovy ($1,349/month) are the most expensive without insurance.

Does Medicare cover Ozempic?

Yes, Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes. Ozempic is on most Part D plan formularies. Your copay depends on your specific plan tier placement, but the 2026 Medicare Part D out-of-pocket cap of $2,100 applies. Medicare does not cover Ozempic when prescribed off-label for weight loss without a diabetes diagnosis.

Does Medicare cover Wegovy?

Yes, but through two pathways. The standard pathway covers Wegovy for patients with established cardiovascular disease and a BMI of 27 or higher (Medicare Part D coverage expanded in 2024 after the FDA approved the cardiovascular risk reduction indication from the SELECT trial). Starting July 2026, the CMS GLP-1 Demonstration Program adds a second pathway covering Wegovy for obesity alone at approximately $50/month copay for eligible Medicare beneficiaries in participating plans, even without a cardiovascular diagnosis.

Does Medicare cover Zepbound?

Yes. Zepbound (tirzepatide for obstructive sleep apnea) became eligible for Medicare Part D coverage in 2025 after FDA approved its OSA indication. OSA is not classified as a lifestyle condition, so the Medicare weight-loss drug exclusion does not apply when Zepbound is prescribed for OSA. Starting July 2026, the CMS GLP-1 Demonstration also covers Zepbound for obesity without requiring an OSA or cardiovascular diagnosis at approximately $50/month copay for eligible Medicare enrollees.

Does Medicaid cover Wegovy or Ozempic?

Most state Medicaid programs cover Ozempic (for diabetes) but not Wegovy (for obesity). Diabetes management is a covered Medicaid benefit in all 50 states, so diabetes-indicated GLP-1s like Ozempic, Mounjaro, Rybelsus, and Trulicity are generally on state formularies with prior authorization. Obesity-indicated GLP-1s like Wegovy and Saxenda are not required to be covered by Medicaid, and fewer than 10 states have voluntarily added them as of 2026.

What is the Mounjaro price under Medicare in 2026?

Mounjaro (tirzepatide) is available to Medicare Part D enrollees through the Trump administration Most Favored Nation deal with Eli Lilly at $245/month, with a $50 copay cap delivered through the TrumpRx platform. This is NOT an IRA Drug Price Negotiation Program result. Tirzepatide is not among the 10 IRA-negotiated drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog/Fiasp) whose Maximum Fair Prices took effect January 1, 2026. Confirm your plan participates in TrumpRx for the $50 copay cap.

Does ACA insurance cover GLP-1 drugs for weight loss?

ACA-compliant plans are not required to cover obesity-indicated GLP-1s like Wegovy or Saxenda because weight-loss drugs are not an ACA Essential Health Benefit. Some plans voluntarily include them, and large employer self-insured plans have broader discretion. ACA plans that cover diabetes medications typically cover diabetes-indicated GLP-1s (Ozempic, Rybelsus, Mounjaro) through their prescription drug benefit, though prior authorization and step therapy are common.

Can I use a manufacturer coupon for GLP-1 drugs?

Manufacturer savings cards (from Novo Nordisk and Eli Lilly) typically apply only to commercially insured patients, not to Medicare or Medicaid beneficiaries. Using a manufacturer coupon when you have federal or state insurance coverage is generally prohibited and can constitute fraud. For uninsured patients, manufacturer patient assistance programs (NovoCare, LillyAnswers) provide free or deeply discounted medication based on income (generally below 400% of the Federal Poverty Level). Check each manufacturer's website for current eligibility criteria.